It is one of those risks that doesn’t announce itself. It just shows up quietly as AI works its way further into regulated life sciences.
AI is not going away. It is going to end up in more of our quality, compliance, manufacturing, and regulatory processes, not fewer. What I keep coming back to is what happens after the initial review, once the technology, the workflow, or the way people actually use it starts to drift from what you signed off on.
Models get updated. Configurations change. Someone connects a new data source. A prompt gets reworded. A workflow grows two steps it did not have last quarter.
Some of that is visible. A lot of it isn’t.
Either way, a system that was fine for a defined use on day one isn’t automatically fine six months later.
This is the part that worries me. A real change to an AI system can happen completely outside the change-control process your quality system depends on to catch, assess, approve, and document it.
The system moved. The paperwork did not.
So governance can’t stop the day the system goes live.
Regulators see it too. The January 2026 FDA and EMA Guiding Principles of Good AI Practice in Drug Development call out context of use, data governance and documentation, risk-based performance assessment, and lifecycle management, including ongoing monitoring and periodic reevaluation.
For anyone running AI in regulated work, I would keep the expectations plain. Know where AI is being used and what for. Understand the GxP impact. Decide which kinds of changes need a second look. Know when a model, configuration, workflow, or use case has shifted enough to matter. Check that performance still holds. Write down the decisions and be clear about who owns them.
None of this is about putting up barriers for the sake of it. It is about still being able to trust the system after it has changed, and being able to show why.
At MEDVACON LIFE SCIENCES, LLC our aim is to help companies get the benefit of AI without giving up the control regulated work demands. We get involved early, before the tool is embedded, to work through intended use, GxP impact, and the governance and verification that need to be in place, and to build a practical way to handle change when it comes.
Then MEDVACON stays with it. As the technology, workflows, and use cases move, we help you figure out what actually needs a fresh look, confirm the outputs still perform the way they should, and keep the documentation and oversight matched to what the system is really doing.
The point is simple: use AI, gain from it, and still be able to stand behind it when an inspector asks.
AI will keep changing. Your quality system should know when it does.
If a platform your organization relies on changed tomorrow, would your quality system even notice?